Analyses of the transcriptomes of the created SIRT2-deficient cell lines revealed the altered expression of numerous genes identified as targets of dasatinib (e.g., EGFR, EPHA2, EPHB1, BTK, MAP3K4, MAP3K14, DDR1, GAK, and LYN) [65,66] (Table 1 and Table 2), which prompted us to examine whether SIRT2 downregulation could sensitize melanoma cells to dasatinib. The gene discussed is LYN; the disease is melanoma.